RESUMEN
The Global Initiative for Asthma Report updated in 2019 stated that potential benefits of allergen immunotherapy (AIT), compared to pharmacological and avoidance options, must be weighed against the risk of adverse effects and the inconvenience and cost of the prolonged course of therapy in asthma. Thus, with the aim of clarifying some aspects with regard to the possible use of AIT in allergic asthma treatment armamentarium, a group of expert allergists from the Spanish Allergy and Clinical Immunology Scientific Society (SEAIC), particularly from the Immunotherapy and Asthma Interest Groups developed a frequently asked questions in clinical practice. This document updates relevant topics on the use of AIT in asthma and could facilitate physician clinical decisions and improve health outcomes for individual patients.
Asunto(s)
Alérgenos/inmunología , Asma/inmunología , Asma/terapia , Desensibilización Inmunológica , Factores de Edad , Especificidad de Anticuerpos/inmunología , Asma/diagnóstico , Biomarcadores , Toma de Decisiones Clínicas , Ensayos Clínicos como Asunto , Análisis Costo-Beneficio , Desensibilización Inmunológica/efectos adversos , Desensibilización Inmunológica/métodos , Manejo de la Enfermedad , Humanos , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Pronóstico , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
OBJECTIVE: Early recognition of symptoms is essential in anaphylaxis management. The Canadian Paediatric Emergency Triage and Acuity Scale prioritizes anaphylaxis to level I or II (resuscitation or emergency). We analyzed the accuracy of pediatric anaphylaxis triage. METHODS: This was a retrospective review of the triage charts (adaptation of the Canadian Paediatric Emergency Triage and Acuity Scale) of 137 children attended for anaphylaxis at our pediatric emergency department. Per triages' accuracy, charts were divided into TR1 (levels I-II) and TR2 (levels III-V), comparing demographics, initial triage level given by initial assessment (Paediatric Assessment Triangle), vital signs, observations recorded by the staff, and waiting times for physician. RESULTS: Forty-six (33.3%) were triaged correctly (TR1 group), and 91 (66.7%) were not. Median ages were similar (TR1: 5 years [interquartile range, 13.1 years] vs TR2: 4.5 years [interquartile range, 14.5 years]; P = 0.837). Initial triage level 5 was given by Paediatric Assessment Triangle to 69.5% of TR1 and 83% of TR2 cases (P = 0.001; likelihood ratio for TR2: 1.985 [95% confidence interval, 1.11-3.49]). Vital signs were normal in 71.7% of TR1 and 94.5% of TR2 patients (P < 0.001; likelihood ratio for TR2: 2.602 [95% confidence interval, 1.22-5.52]). Symptoms suggestive of anaphylaxis (mention of 2 different organs) were recorded in 45.6% of TR1 and 48.3% of TR2 charts (P = 0.08). Median waiting times were 3 minutes (interquartile range, 26 minutes) and 11 minutes (interquartile range, 111 minutes) for TR1 and TR2, respectively (P = 0.001). CONCLUSIONS: Current triage, based on severity perception, missed most of the cases. Anaphylaxis-defining symptoms were overlooked. Inaccurate triage delayed medical attention. Improving measures, such as emphasizing symptom recognition and defining anaphylaxis risk discriminators, is mandatory to improve their identification.
Asunto(s)
Anafilaxia , Servicio de Urgencia en Hospital/normas , Triaje , Adolescente , Anafilaxia/diagnóstico , Canadá , Niño , Humanos , Estudios Retrospectivos , Triaje/normasRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adulto Joven , Anafilaxia/inducido químicamente , Miel/efectos adversos , Enema/efectos adversos , Administración RectalAsunto(s)
Anafilaxia/diagnóstico , Condroitinsulfatasas/efectos adversos , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/diagnóstico , Terapia de Reemplazo Enzimático/efectos adversos , Reacción en el Punto de Inyección/diagnóstico , Omalizumab/uso terapéutico , Alérgenos/inmunología , Prueba de Desgranulación de los Basófilos , Preescolar , Condroitinsulfatasas/inmunología , Condroitinsulfatasas/uso terapéutico , Humanos , Tolerancia Inmunológica , Inmunoglobulina E/metabolismo , Masculino , Mucopolisacaridosis IV , Pruebas Cutáneas , UrticariaAsunto(s)
Anafilaxia/inducido químicamente , Anafilaxia/inmunología , Antiinfecciosos Locales/inmunología , Clorhexidina/inmunología , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad Inmediata/inducido químicamente , Hipersensibilidad Inmediata/inmunología , Antiinfecciosos Locales/efectos adversos , Preescolar , Clorhexidina/efectos adversos , Hipersensibilidad a las Drogas/inmunología , Humanos , MasculinoAsunto(s)
Anafilaxia/inducido químicamente , Proteínas Bacterianas/efectos adversos , Hipersensibilidad a las Drogas/etiología , Vacunas Neumococicas/efectos adversos , Anafilaxia/diagnóstico , Anafilaxia/inmunología , Proteínas Bacterianas/administración & dosificación , Proteínas Bacterianas/inmunología , Prueba de Desgranulación de los Basófilos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/inmunología , Humanos , Esquemas de Inmunización , Lactante , Pruebas Intradérmicas , Masculino , Vacunas Neumococicas/administración & dosificación , Vacunas Neumococicas/inmunología , Valor Predictivo de las Pruebas , Ruidos Respiratorios , Factores de Riesgo , Urticaria/inducido químicamente , Urticaria/diagnóstico , Urticaria/inmunologíaRESUMEN
BACKGROUND: Subcutaneous immunotherapy (SCIT) discontinuation data in children remain scarce. OBJECTIVE: We sought for differences in the clinical efficacy of 3 vs. 5 yr of SCIT in children with dust mite respiratory allergy. METHODS: We performed a 5-yr, phase IV prospective study. After the first year, the patients were randomized to 3 (IT3) or 5 yr of treatment (IT5). Efficacy was assessed at 3rd and 5th year by symptom and medication scores and visual analog scales (VAS). Skin tests with common allergens and in vitro assessments were also performed. RESULTS: Eighty-one children (mean age: 9 yr) were randomly assigned to 3 (IT3: 41) or 5 yr (IT5: 40) of immunotherapy. After 3 years, rhinitis global scores decreased in IT3 (44%; p = 0.002) and in IT5 (50%; p = 0.001). Asthma global, symptom and medication scores decreased by 100% in IT3 (p = 0.001) and IT5 (p = 0.001). VAS scores also diminished significantly (IT3: 70%, p = 0.001; IT5: 62.5%; p = 0.001). At 5th year, global rhinitis scores were reduced an additional 30% in IT5 children. Comparisons between both groups did not show differences in rhinitis (p = 0.055), asthma global scores (p = 0.948) or VAS scores at 5th year. Twenty percent of IT5 (p = 0.002) and 7% of IT3 children (p = 0.705) developed new sensitizations. At 5th year, sIgG4 determinations decreased in IT3 without significant variations in IT5. CONCLUSIONS: Three years of SCIT induced significant improvement in children with dust mite respiratory allergy, but a 5-yr course added clinical improvement in rhinitis.
Asunto(s)
Desensibilización Inmunológica , Hipersensibilidad Respiratoria/terapia , Factores de Tiempo , Animales , Antígenos Dermatofagoides/inmunología , Niño , Protocolos Clínicos , Revisión de la Utilización de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Subcutáneas , Masculino , Estudios Prospectivos , Pyroglyphidae , Hipersensibilidad Respiratoria/inmunología , Pruebas Cutáneas , Resultado del TratamientoRESUMEN
BACKGROUND: Specific immunotherapy (SIT) duration for respiratory allergy is currently based on individual decisions. OBJECTIVE: To evaluate the differences in clinical efficacy of SIT as a result of the duration between the current recommended limits (3-5 years). METHODS: A 5-year prospective, controlled clinical trial of SIT blind until the first year and randomization to a 3-year (IT3) or 5-year (IT5) course was conducted. Of the 239 patients with respiratory allergy caused by D pteronyssinus initially included, 142 completed 3 years of SIT with good compliance. Twenty-seven controls were included at the third year. Efficacy of SIT after 3 (T3) and 5 (T5) years was assessed by using clinical scores, visual analog scales (VASs), rhinitis (RQLQ) and asthma (AQLQ) quality of life questionnaires, skin tests, and serum immunoglobulins. RESULTS: At T3, significant reductions were observed in rhinitis (44% in IT3 and 50% in IT5; P < .001), asthma (80.9 % in IT3 and 70.9% in IT5; P < .001) scores, VAS (P < .001 in both), RQLQ (P < .001 in both) and AQLQ (P < .001 in both). At T5, the clinical benefit was maintained in both groups, and IT5 patients presented additional decreases (19%; P = .019) in rhinitis scores. At Tf, specific IgG(4) measurements were lower in IT3 (P = .03) without detecting differences in IT5. An increase in asthma score of 133% was the only difference observed in controls. CONCLUSION: Clinical improvement is obtained with 3 years of D pteronyssinus SIT. Two additional years of SIT add clinical benefit in rhinitis only.